Consistent with our findings, Gélinas, R. et al. (2018) demonstrated that submaximal AMPK activation appears to counteract cardiac hypertrophy by reducing O-GlcNAcylation [65]. Here, PRKAA2 is linked to cardiac hypertrophy.